Intravitreal ranibizumab in choroidal neovascularisation due to multifocal choroiditis and panuveitis syndrome

    loading  Checking for direct PDF access through Ovid

Abstract

We report the use of intravitreal ranibizumab as initial and only treatment in a case of peripapillary choroidal neovascularisation (CNV) in a patient with multifocal choroiditis and panuveitis (MCP) syndrome. A 54-year-old woman presented with sudden reduced vision in the right eye of 2 weeks duration. A full ophthalmological examination was performed including biomicroscopy, fluorescein angiography and optical coherence tomography. A peripapillary choroidal neovascular membrane with subretinal haemorrhage extending to the fovea was revealed due to MCP syndrome. Three intravitreal injections of ranibizumab were performed with monthly intervals. There was clearance of the subretinal haemorrhage and reduction of the leakage after the first injection. The visual acuity improved to 20/20 in 3 months and remained stable at 2-year follow-up without angiographical leakage. Intravitreal injections of ranibizumab could be tried in cases of CNV due to MCP syndrome with very good response.

Related Topics

    loading  Loading Related Articles